Daily Hand-Held Vibration Therapy

Inclusion criteria

• 18 years or older at enrollment
• Able to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
• Have completed chemotherapy ≥ 60 days prior to enrollment
• Were exposed to neurotoxic chemotherapy with one or more of the following agents in the following doses: Paclitaxel (cumulative dose: ≥ 300 mg/m2) Docetaxel (cumulative dose: ≥ 100 mg/m2) Nab-paclitaxel (cumulative dose: ≥ 750 mg/m2) Oxaliplatin (cumulative dose: ≥ 510 mg/m2) Carboplatin (cumulative dose: ≥ 600 mg/m2) Cisplatin (cumulative dose: ≥ 200 mg/m2) Vincristine (cumulative dose: ≥ 4 mg/m2) Bortezomib (cumulative dose: ≥ 16 mg/m)
• Continue to display evidence of sensory CIPN in the hands rated at a Grade ≥ 2 according the National Cancer Institute's Common Toxicity Criteria-Adverse Events (NCI-CTC-AE, Version 5.0) Scale ≥ 60 days post-chemotherapy
• If solid tumor cancer, must have non-metastatic cancer
• Agree to return to clinic for required study related measurements at specified intervals

Exclusion criteria

• Have pre-existing neuropathy affecting the hands not related to chemotherapy (e.g., carpal tunnel syndrome, nerve compression, etc.)
• Known diagnosis of diabetes mellitus.
• Known contraindications for vibration therapy to hands, including deep venous thrombosis of the upper extremity or ongoing skin infection.
• Will be receiving concurrent radiation of the upper-extremity